Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng, Shandong 252059, People's Republic of China.
School of Geography and Environment, Liaocheng University, Liaocheng, Shandong 252059, People's Republic of China.
Int J Biol Macromol. 2023 Dec 31;253(Pt 1):126639. doi: 10.1016/j.ijbiomac.2023.126639. Epub 2023 Aug 30.
Solid dispersions (SDs) possess the potential to enhance the bioavailability of insoluble active pharmaceutical ingredients (APIs) by effectively converting them into amorphous state. However, SDs have a tendency to recrystallize unless appropriate excipients are employed. The objective of this study was to evaluate the ability of hypromellose acetate succinate HF (HPMCAS-HF) and Soluplus® to inhibit the recrystallization of β-carotene and improve its in vivo bioavailability through the fabrication of ternary β-carotene solid dispersions (SDs) with the aid of specific surfactant. Due to rapid micellization, the dissolution profiles of β-carotene SDs based on HPMCAS-HF/Span 20 (5:5, w/w) or Soluplus®/Span 20 (6:4, w/w) combinations exhibited significant improvement, which were almost 7-10 times higher than β-carotene bulk powder. DSC and PXRD analysis indicated a notable reduction in the crystallinity degree of β-carotene within the SDs. The stability study demonstrated a half-life of β-carotene in the SDs exceeding 30 days. Additionally, the in vivo pharmacokinetics analysis confirmed that the cellulose derivatives/surfactant combinations significantly enhanced the bioavailability of β-carotene by 1.37-fold and 2.3-fold, respectively. Notably, the HPMCAS-HF/Span 20 combination exhibited superior performance. Consequently, the HPMCAS-HF/Span 20 combination held potential for the advancement of an effective drug delivery system for β-carotene.
固体分散体(SDs)具有将难溶性活性药物成分(APIs)有效转化为无定形态从而提高其生物利用度的潜力。然而,除非使用适当的赋形剂,否则 SDs 有重新结晶的趋势。本研究的目的是评估醋酸羟丙甲纤维素琥珀酸酯 HF(HPMCAS-HF)和 Soluplus®通过使用特定表面活性剂制备β-胡萝卜素的三元固体分散体(SDs)来抑制β-胡萝卜素的再结晶并提高其体内生物利用度的能力。由于快速胶束化,基于 HPMCAS-HF/Span 20(5:5,w/w)或 Soluplus®/Span 20(6:4,w/w)组合的β-胡萝卜素 SDs 的溶解曲线显示出显著改善,几乎是β-胡萝卜素块状粉末的 7-10 倍。DSC 和 PXRD 分析表明 SDs 中β-胡萝卜素的结晶度显著降低。稳定性研究表明 SDs 中β-胡萝卜素的半衰期超过 30 天。此外,体内药代动力学分析证实纤维素衍生物/表面活性剂组合分别将β-胡萝卜素的生物利用度提高了 1.37 倍和 2.3 倍。值得注意的是,HPMCAS-HF/Span 20 组合表现出卓越的性能。因此,HPMCAS-HF/Span 20 组合有望成为β-胡萝卜素有效药物递送系统的进步。